Immunewalk Therapeutics Inc. /
Vascular Biogenics Ltd.
Immunewalk Therapeutics to buy assets from Vascular Biogenics Ltd.
What happened
Immunewalk Therapeutics Inc. agreed to purchase VB-601 and MOSPD2 related assets from Vascular Biogenics Ltd. The asset purchase agreement was signed on Oct. 1, 2023.
Payment terms include $250,000 at closing and additional payments of up to $4.75 million upon clinical and commercial milestones.
The source
Everything on this page comes from the source below.
Immunewalk Therapeutics to buy assets from Vascular Biogenics Ltd.
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Agreement signed
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly